Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on TVTX stock, giving a Buy rating on August 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Travere Therapeutics’ promising outlook. The recent approval of a supplemental New Drug Application for Filspari, which modifies the Risk Evaluation and Mitigation Strategies, is a significant milestone. This adjustment allows for less frequent liver function testing, aligning with clinical trial experiences and potentially expanding the patient population for Filspari in IgA nephropathy. The removal of the embryo-fetal toxicity warning further enhances the drug’s appeal.
Additionally, Travere’s strong performance in the second quarter has led to increased sales estimates, with projections for 2025 now at $300 million, surpassing consensus expectations. The focus on the opportunity in focal segmental glomerulosclerosis (FSGS) is also a key driver, with an upcoming Advisory Committee meeting that could further bolster the drug’s market potential. The combination of these regulatory advancements and market opportunities underpins Schwartz’s optimistic outlook for Travere Therapeutics.
According to TipRanks, Schwartz is a 5-star analyst with an average return of 18.4% and a 49.90% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Ascendis Pharma.
In another report released on August 28, Canaccord Genuity also maintained a Buy rating on the stock with a $47.00 price target.